Overview

Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma

Status:
Completed

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

Summary

A comparator study to assess safety and efficacy of Flutiform® compared with symbicort turbohaler in asthma patients with moderate to severe persistent, reversible asthma.

Phase:

Phase 3

Details

Lead Sponsor:

Mundipharma Research Limited

Treatments:

Budesonide, Formoterol Fumarate Drug Combination